On November 20, 2020 Shanghai Antengene, a three-year old oncology company, reported that it completed a $340 million IPO in Hong Kong (Press release, Antengene, NOV 20, 2020, View Source [SID1234571518]). The company, which was originally backed by Celgene, said the offering was significantly oversubscribed . Antengene has built a portfolio of 12 first-in-class, only-in-class and best-in-class cancer therapies, six of which have begun clinical trials. It combines in-licensings with internal research. The company says it uses a synergistic approach to "unlock the full therapeutic potential" of its candidates.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!